九旬患者腹主动脉瘤修复术后30天死亡预测因素:NSQIP数据分析
本研究利用美国外科医师学会国家手术质量改进计划(NSQIP)数据集,识别接受腹主动脉瘤修复术的九旬患者30天死亡的预测因素。共纳入1356例,其中EVAR 1229例(90.6%),开放手术(OSR)127例(9.4%),总体30天死亡率为10.4%。死亡组更多接受OSR、依赖功能状态、ASA≥4、围术期输血、术后肺炎、机械通气>48小时和急性肾衰竭。结论认为九旬患者EVAR的30天死亡率递增但可接受,依赖状态、高ASA分级、急诊修复和OSR与更高死亡率相关。
要点
- 九旬患者腹主动脉瘤修复术后30天总死亡率为10.4%。
- 死亡组中OSR比例(40.9%)显著高于EVAR(7.2%)。
- 依赖功能状态、ASA≥4、急诊修复和OSR是死亡预测因素。
核心结论
- 九旬患者接受EVAR的30天死亡率在择期和急诊病例中递增但可接受。
- 依赖功能状态、较高ASA分级、急诊修复和OSR与更高的30天死亡率相关。
- 这些术前危险因素有助于识别最佳手术候选人。
研究设计与样本
- 回顾性队列研究,使用美国外科医师学会NSQIP数据集。
- 纳入2005至2017年接受腹主动脉瘤修复的年龄>90岁患者,排除手术时间<15分钟者。
- 共1356例九旬患者,其中EVAR 1229例(90.6%),OSR 127例(9.4%)。
主要发现
- 总体30天死亡率为10.4%。
- 死亡组OSR比例40.9%,存活组7.2%(P < .001)。
- 死亡组依赖功能状态22.0% vs 8.1%(P < .001),ASA≥4 81.2% vs 18.8%(P < .001)。
- 死亡组围术期输血59.6% vs 20.3%(P < .001),术后肺炎12.1% vs 2.9%(P = .001)。
- 死亡组机械通气>48小时22.7% vs 2.6%(P < .001),急性肾衰竭12.1% vs 0.5%(P < .001)。
关键数值与推荐
- EVAR组择期病例30天死亡率2.6%(1008例),急诊病例28.6%(221例)。
- OSR组择期病例30天死亡率19.1%(47例),急诊病例53.7%(80例)。
- EVAR队列中死亡组依赖功能状态17% vs 8%(P = .004),ASA≥4 76.4% vs 40.3%(P < .001)。
- EVAR队列中死亡组围术期输血57% vs 19%(P < .001),急诊手术71% vs 14%(P < .001),手术时间150 vs 128分钟(P = .001)。
临床怎么用
- 对于九旬腹主动脉瘤患者,应评估功能状态和ASA分级以识别高风险患者。
- EVAR在择期和急诊病例中均可考虑,尤其对高度选择的患者。
- 择期患者若腹主动脉瘤直径较大、破裂风险较高,可考虑EVAR或OSR。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The present study used the American College of Surgeons National Surgical Quality Improvement Program dataset to identify the predictors of 30-day mortality for nonagenarians undergoing endovascular aortic aneurysm repair (EVAR) or open surgical repair (OSR). METHODS: Patients aged >90 years who had undergone abdominal aortic aneurysm repair from 2005 to 2017 were identified using procedure codes. Those with operative times <15 minutes were excluded. The demographics, preoperative comorbidities, and postoperative complications of those who had died by 30 days were compared with those of the patients alive at 30 days. RESULTS: A total of 1356 nonagenarians met the criteria: 1229 (90.6%) had undergone EVAR and 127 (9.4%) had undergone OSR. The overall 30-day mortality was 10.4%. The patients who had died within 30 days were significantly more likely to have undergone OSR than EVAR (40.9% vs 7.2%; P < .001). They also had a greater incidence of dependent functional status (22.0% for those who had died vs 8.1% for those alive at 30 days; P < .001), American Society of Anesthesiology (ASA) classification of ≥4 (81.2% vs 18.8%; P < .001), perioperative blood transfusion (59.6% vs 20.3%; P < .001), postoperative pneumonia (12.1% vs 2.9%; P = .001), mechanical ventilation >48 hours (22.7% vs 2.6%; P < .001), and acute renal failure (12.1% vs 0.5%; P < .001). The EVAR group had a 30-day mortality rate of 2.6% in 1008 elective cases and 28.6% in 221 emergent cases. The OSR group had a 30-day mortality rate of 19.1% in 47 elective cases and 53.7% in 80 emergent cases. In the EVAR cohort, the 30-day mortality group had had a significantly greater incidence of dependent functional status (17% for those who had died vs 8% for those alive at 30 days; P = .004), ASA classification of ≥4 (76.4% vs 40.3%; P < .001), perioperative blood transfusion (57% vs 19%; P < .001), emergency surgery (71% vs 14%; P < .001), and longer operative times (150 vs 128 minutes; P = .001). CONCLUSIONS: Nonagenarians had an incrementally increased, but acceptable, risk of 30-day mortality with EVAR in elective and emergent cases compared with that reported for octogenarians and cohorts of patients not selected for age. We found greater mortality for patients with dependent status, a higher ASA classification, emergent repair, and OSR. These preoperative risk factors could help identify the best surgical candidates. Given these results, consideration for EVAR or OSR might be reasonable for highly selected patients, especially for elective patients with a larger abdominal aortic aneurysm diameter for whom the risk of rupture is higher.
引用
- Kumar M, Long GW, Major M, et al. Predictors of mortality in nonagenarians undergoing abdominal aortic aneurysm repair: Analysis of the National Surgical Quality Improvement Program dataset. J Vasc Surg. 2021. PMID: 34634420. doi:10.1016/j.jvs.2021.09.041
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。